Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
57 participants
INTERVENTIONAL
2017-06-25
2018-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals
NCT03203824
Effect of Phytochemicals From Theobroma Cacao on Mental Energy
NCT01651793
Effects of a Cocoa Shot on the Human Brain 2
NCT02080845
Effects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases
NCT06808282
Effects of a Cocoa Shot on the Human Brain
NCT01924481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 30 subjects will be recruited from UIW and RSO students, staff, faculty and patients. The age range will be 18 to 65 years and the investigators will attempt to include comparable numbers of male and female participants. Inclusion criteria include visual acuity of at least 20/20 in each eye with no evidence of ocular, systemic or neurologic disease or ocular trauma. Based on prior research using repeated-measures designs, a difference of 0.1 log CS is considered significant and the estimated standard deviation is 0.13 log units. Hence the effect size = (mean difference)/SD = 0.1/0.13 = 0.76. The estimated minimum number of subjects to achieve significance at the 5% level with a power of 80%: (1/effect size)2 x 16 = (1/0.76)2 x 16 = 28 subjects.(8,9). Hence 30 subjects will be recruited to account for subject attrition during the course of the study. Prior to obtaining written informed consent, each subject will be briefed on the nature of the study by one or more members of the research team. Subjects will be informed that they will be evaluated with standard vision tests one hour after consuming a chocolate bar to assess its effects on performance. The dark chocolate and milk chocolate bars to be used are commercially available from Trader Joe's and have comparable ingredients and nutrients except for the higher percentage (72%) of cacao dark chocolate in the experimental bar while the control bar contains 31% milk chocolate cocao solids which are not associated with acute beneficial effects on performance. As stated in the informed consent document, subjects will be asked if they have allergies to any of the ingredients contained in the chocolate bars, and will be excluded from participating if they answer affirmatively. As noted above, any subjects with ocular, systemic or neurologic disease, including diabetes and hypoglycemia, will not be allowed to participate in the study.
A single-blinded crossover design will be used to assess possible effects of the dark or milk chocolate bars (72% cacao dark chocolate) on visual performance and visual electrophysiological signals. Double-blinding (experimenter unaware of the type of chocolate) is not tenable due to the difference in coloration and aroma of the two chocolate bars and not likely to be a significant source of variability given the objective nature of the visual performance measures. Subjects will be tested in two one-hour sessions separated by at least 72 hours. Each subject will consume a different chocolate bar one-hour prior to testing with the order of bars (dark vs. milk chocolate) counter-balanced across subjects. Subjects will be asked to refrain from consuming coffee or caffeinated drinks on the day of testing and to consume the bar without milk or milk products which can lessen beneficial effects of dark chocolate. The subject will be presented the bar in its original wrapper but with the name masked by tape and she/he will be given a paper plate and napkins and asked to remove and return the wrapping to the research team member(s). The subject will be offered water during consumption of the bar which will take place in the research room. Insofar as many of the subjects will be in-house student volunteers, she/he will then remain in UIWRSO to study, work-study, finish clinical records, etc. for about 30 minutes. The patient will then undergo preliminary evaluation to prepare for the testing to commence at least 1 hour after chocolate bar consumption. This will include measurement of distant visual acuity followed by refraction to best visual acuity if the patient does not achieve 20/20 in each eye with their habitual correction. Hence the patient will either wear their habitual correction or lenses in a trial frame to achieve best vision during testing. The patient will then be prepped for electro-diagnostic testing including visual-evoked potentials (VEPs) and electro-retinograms (ERGs) which objectively assess visual cortical and retina/optic nerve function, respectively. VEPs will be recorded using the Diopsys® system. The subject is seated comfortably before a reversing checkerboard display. The back of the head, forehead and temple will be wiped clean using an FDA approved non-abrasive cleaner. High and low contrast VEPs will be recorded from the back of the head using disposable skin electrodes with reference and ground electrodes at the forehead and temple, respectively. Cone specific color VEPs10 will also be recorded using the Diagnosys, LLC system. All VEPs will be recorded binocularly and not be initiated until one-hour following consumption of the chocolate bar. The Diopsys® system will be used to record pattern ERGs (optic nerve function), flicker ERGs (cone function) and the photopic negative response (phNR; cone, bipolar cell and optic nerve function). Half of the subjects in control and experimental sessions will be tested with ERGs first and half with VEPs first to control for order effects. These FDA approved electro-diagnostic tests will be followed by letter chart measures of large and small CS (Precision Vision, Inc.). Each subject will then be tested with the Innova Systems, Inc. computer controlled Cone Contrast Test which assesses red, green and blue cone CS as well as large and small black/white letter CS using an adaptive staircase (like a hearing test) to determine the lowest visible contrast and overall response time. As described in our previous study,7 each subject will undergo computer-based CS testing with and without verbal distraction during testing with order counterbalanced across subjects. The verbal distraction will be broadcast on a hands-free blue-tooth device to simulate an incoming phone call consisting of scripted questions to assess memory and cognitive performance while completing the CS tasks. Following these tests, the subject will be asked to perform a brief (\<10 minute) Wii™ shooting game using the Wii™ zapper which is shaped like a small rifle-no training is necessary. Two-way repeated measures ANOVA will be used to assess CS across distraction and chocolate bar conditions and post-hoc paired t-tests conducted to identify specific differences. Within subject ANOVAs and post-hoc t-test comparisons also will be used to assess amplitude and latency parameters of VEPs and ERGs across dark and milk chocolate conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Milk Chocolate
Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
Milk Chocolate
Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
Dark Chocolate
Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
Dark chocolate
Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dark chocolate
Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
Milk Chocolate
Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absence of ocular disease
* Absence of ocular trauma
* Absence of systemic disease
* Absence of neurologic disease
Exclusion Criteria
* Presence of ocular disease
* Presence or history of ocular trauma
* Presence of systemic disease
* Presence of neurologic disease
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of the Incarnate Word
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeff C Rabin, OD, MS, PhD
Role: PRINCIPAL_INVESTIGATOR
University of the Incarnate Word
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of the Incarnate Word Rosenberg School of Optometry
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rabin JC, Karunathilake N, Patrizi K. Effects of Milk vs Dark Chocolate Consumption on Visual Acuity and Contrast Sensitivity Within 2 Hours: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jun 1;136(6):678-681. doi: 10.1001/jamaophthalmol.2018.0978.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-06-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.